undamentalytics Newsletter
Sign in

United Therapeutics Corp income statement

In fiscal 2025, United Therapeutics Corp reported revenue of $3.18bn, up 10.6% on the year before, operating income of $1.49bn (a 46.9% margin) and net income of $1.33bn, or $27.86 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue3595937439161,1171,2891,4661,5991,7251,6281,4491,4831,6861,9362,3282,8773,1833,155
Cost of revenue———————73106199118108123152258310384437
Gross profit3175246527879761,154—1,5261,6201,4291,3311,3751,5631,7852,0702,5682,7982,717
Research and development1201651801732992432451482653581,183358540323408481550552
Selling, general and administrative172189156202394381453317330266——467482477710756764
Operating income261713184222925396991,062815805−1885945569801,1851,3771,4931,402
Interest expense132021171818549144424193259432012
Income before tax191552994412795251,0441,060770759−1656395949511,2741,5391,7141,573
Income tax−14482136104185393347352170−61124118223290344379262
Net income19106218304175340652714418589−1055154767279851,1951,3351,311
Diluted EPS$0.35$1.78$3.67$5.71$3.28$6.28$12.72$15.25$9.31$13.39−$2.39$11.54$10.06$15.00$19.81$24.64$27.86$27.94
Diluted shares (average)56m60m59m53m53m54m51m47m45m44m44m45m47m49m50m49m48m47m
EBITDA371893384493245717321,093846841−1426446061,0311,2381,4501,5781,493

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BNTX vs UTHRBMRN vs UTHRNTRA vs UTHREXEL vs UTHR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from United Therapeutics Corp's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to United Therapeutics Corp.